Akari Therapeutics Plc
Business
Akari Therapeutics is an oncology company developing antibody-drug conjugates (ADCs) with novel payloads targeting RNA splicing. Its lead payload PH1 modulates the spliceosome to kill cancer cells and generate neoantigens that activate the immune system. The company's lead candidate AKTX-101 targets Trop-2 and is advancing toward first-in-human Phase 1 trials; AKTX-102 targets CEACAM5 in discovery stage. Akari operates as a preclinical and early-stage clinical-development company with no approved products, relying on third-party contract manufacturers and seeking future partnerships or commercialization strategies.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2015 2015-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 3 | 7 | 5 | 10 | 6 | |
| General and administrative | 9 | 10 | 11 | 14 | 6 | |
| Impairment loss on other intangible assets | 5 | — | — | — | — | |
| Merger-related expenses | — | 3 | — | — | — | |
| Restructuring and other expenses | — | 2 | — | — | — | |
| Total operating expenses | 17 | 22 | 17 | — | 31 | |
| Loss from operations | −17 | −22 | −17 | −23 | −31 | |
| Interest income | 1,000 | 8,000 | 82,000 | 46,000 | 20,705 | |
| Interest expense | −949,000 | −244,000 | — | — | — | |
| Gain on settlement of current liabilities | 3 | — | — | — | — | |
| Loss on debt extinguishment | −3 | — | — | — | — | |
| Change in fair value of warrant liabilities | 775,000 | 2 | 7 | 7 | 11 | |
| Loss on derivative liability | −230,000 | — | — | — | — | |
| Foreign currency exchange gains (losses), net | −443,000 | 6,000 | 136,000 | 453,000 | — | |
| Other expense, net | — | −3,000 | — | — | — | |
| Total other income, net | −1 | 2 | 7 | — | −15 | |
| Net loss before income taxes | −18 | −20 | — | — | −45 | |
| Income tax benefit | 1 | — | — | — | 0 | |
| Net loss | −17 | −20 | −10 | −18 | −45 | |
| Net loss per share - basic | 0 | 0 | 0 | 0 | — | |
| Net loss per share - diluted | 0 | 0 | 0 | 0 | — | |
| Weighted-average number of Ordinary Shares used in computing net loss per share - basic | 67,328 | 23,888 | 9,789 | 6,243 | — | |
| Weighted-average number of Ordinary Shares used in computing net loss per share - diluted | 67,328 | 23,888 | 9,789 | 6,243 | — | |
| Foreign currency translation adjustment | −44,000 | 302,000 | −269,000 | −230,000 | 110,399 | |
| Total other comprehensive income, net of tax | −44,000 | 302,000 | −269,000 | −230,000 | — | |
| Total comprehensive loss | −17 | −19 | −10 | −18 | −45 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 5 | 3 | — | — | — | |
| Restricted cash | 60,000 | 60,000 | 0 | — | — | |
| Prepaid expenses | 185,000 | 92,000 | 299,000 | 465,000 | — | |
| Other current assets | 14,000 | 201,000 | 197,000 | 100,000 | — | |
| Total current assets | 5 | 3 | 4 | 14 | — | |
| Goodwill | 8 | 8 | — | — | — | |
| Other intangible assets | 34 | 39 | — | — | — | |
| Total assets | 48 | 51 | 4 | 14 | — | |
| Accounts payable | 9 | 12 | 2 | 947,000 | — | |
| Accrued expenses | 2 | 3 | 2 | 3 | — | |
| Convertible notes, net | 673,000 | 700,000 | — | — | — | |
| Convertible notes, related party | — | 250,000 | — | — | — | |
| Notes payable, net | 81,000 | 659,000 | — | — | — | |
| Notes payable, related party | — | 2 | — | — | — | |
| Warrant liabilities | 61,000 | 1 | 1 | 8 | — | |
| Other current liabilities | 424,000 | 94,000 | 94,000 | 94,000 | — | |
| Total current liabilities | 12 | 20 | 5 | — | — | |
| Derivative liability | 230,000 | — | — | — | — | |
| Other non-current liabilities | 31,000 | 383,000 | — | — | — | |
| Deferred tax liability | 7 | 8 | — | — | — | |
| Total liabilities | 20 | 28 | 5 | 12 | — | |
| Commitments and contingencies (Note 11) | — | — | — | — | — | |
| Share capital of $0.000000005 par value Authorized: 761,963,201,733 and 245,035,791,523 ordinary shares at December 31, 2025 and December 31, 2024, respectively; issued and outstanding: 90,536,879,533 and 53,186,919,523 ordinary shares at December 31, 2025 and December 31, 2024, respectively | — | 5 | 1 | 745,000 | — | |
| Additional paid-in capital | 234 | 213 | — | — | — | |
| Capital redemption reserve | 59 | 52 | 52 | 52 | — | |
| Accumulated other comprehensive loss | −782,000 | −738,000 | −1 | −771,000 | — | |
| Accumulated deficit | −265 | −247 | −227 | −217 | — | |
| Total shareholders equity | 28 | 22 | −229,000 | 2 | 6 | |
| Total liabilities and shareholders equity | 48 | 51 | 4 | 14 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2015 2015-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | — | 14,000 | 4,000 | 4,000 | — | |
| Stock-based compensation | 3 | 2 | 1 | 735,000 | 1 | |
| Issuance of shares for services | 27,000 | 271,000 | 142,000 | — | 750,000 | |
| Accretion of debt issuance costs | 589,000 | — | — | — | — | |
| Impairment loss on other intangible assets | 5 | — | — | — | — | |
| Deferred income tax benefit | −1 | — | — | — | — | |
| Unrealized foreign currency exchange losses (gains) | −99,000 | 255,000 | −255,000 | −334,000 | — | |
| Prepaid expenses and other current assets | 594,000 | 1 | — | — | — | |
| Accounts payable and accrued expenses | −998,000 | 5 | −936,000 | −877,000 | 4 | |
| Net cash used in operating activities | −11 | −13 | −16 | −22 | −5 | |
| Cash acquired in Peak Bio Acquisition | — | 382,000 | — | — | 1 | |
| Net cash provided by investing activities | — | 382,000 | — | — | 1 | |
| Proceeds from issuance of shares, net of issuance costs | 11 | 12 | 7 | 25 | 75 | |
| Proceeds from issuance of warrants | 1 | — | — | — | — | |
| Proceeds from issuance of notes payable | 2 | — | — | — | — | |
| Proceeds from issuance of convertible notes | — | 1 | — | — | — | |
| Repayment of notes payable and convertible notes | −553,000 | −750,000 | — | — | — | |
| Proceeds from issuance of restricted shares | — | 26,000 | — | — | 0 | |
| Proceeds from employee vesting of restricted shares | 33,000 | 2,000 | 4,000 | — | — | |
| Proceeds from pre-funded warrants | 330,000 | — | — | 94,000 | — | |
| Payments on seller-financed purchases | −499,000 | −1 | — | — | — | |
| Net cash provided by financing activities | 13 | 11 | 7 | 25 | 69 | |
| Effect of exchange rates on cash | 1,000 | −4,000 | 7,000 | 105,000 | — | |
| Net change in cash | 3 | −1 | −9 | 4 | — | |
| Financing costs in accounts payable and accrued expenses | — | 348,000 | 55,000 | — | — | |
| Seller-financed purchases | 499,000 | 1 | — | — | — | |
| Issuance of share capital for settlement of convertible notes, related party | 309,000 | — | — | — | — | |
| Issuance of share capital for settlement of related party debt | 1 | — | — | — | — | |
| Issuance of share capital for payments in kind | 595,000 | — | — | — | — | |
| Modification of warrants in connection with issuance of notes payable | 3 | — | — | — | — | |
| Modification of warrants in connection with amendment of convertible notes | 192,000 | — | — | — | — | |
| Issuance of warrants in connection with note exchange and cancellation | 4 | — | — | — | — | |
| Payroll taxes on stock-based compensation in accrued expenses | — | 193,000 | — | — | — | |
| Issuance of ordinary shares for Peak Bio Acquisition | — | 28 | — | — | — | |
| Warrants assumed in connection with Peak Bio Acquisition | — | 2 | — | — | — | |
| Cash paid for interest | 101,000 | 143,000 | — | — | — | |
| Cash paid for income taxes | — | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Akari Therapeutics Plc's CIK number?
Akari Therapeutics Plc's SEC CIK number is 0001541157 (1541157). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Akari Therapeutics Plc's SEC filings?
All of Akari Therapeutics Plc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Akari Therapeutics Plc last report earnings?
Akari Therapeutics Plc (AKTX) most recently filed an earnings 8-K with the SEC on May 15, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000950170-25-072046). This is Akari Therapeutics Plc's most recent earnings filing of record — not a forecast of its next earnings date.
What is Akari Therapeutics Plc's most recent earnings 8-K?
Akari Therapeutics Plc's latest earnings 8-K (Item 2.02) was filed May 15, 2025 under accession 0000950170-25-072046. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Akari Therapeutics Plc's latest earnings 8-K →
Look up any company's CIK number →